Advisor Group Inc. raised its holdings in LeMaitre Vascular Inc (NASDAQ:LMAT) by 28.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,033 shares of the medical instruments supplier’s stock after buying an additional 1,550 shares during the period. Advisor Group Inc.’s holdings in LeMaitre Vascular were worth $223,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of the business. Conestoga Capital Advisors LLC grew its holdings in shares of LeMaitre Vascular by 55.3% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,327,376 shares of the medical instruments supplier’s stock worth $42,264,000 after purchasing an additional 472,732 shares during the last quarter. Biondo Investment Advisors LLC purchased a new position in shares of LeMaitre Vascular during the fourth quarter worth about $3,714,000. BlackRock Inc. grew its holdings in shares of LeMaitre Vascular by 3.8% during the fourth quarter. BlackRock Inc. now owns 2,265,936 shares of the medical instruments supplier’s stock worth $72,150,000 after purchasing an additional 82,607 shares during the last quarter. Nationwide Fund Advisors grew its holdings in shares of LeMaitre Vascular by 71.7% during the third quarter. Nationwide Fund Advisors now owns 120,793 shares of the medical instruments supplier’s stock worth $4,520,000 after purchasing an additional 50,431 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of LeMaitre Vascular by 30.5% during the third quarter. Janus Henderson Group PLC now owns 194,891 shares of the medical instruments supplier’s stock worth $7,293,000 after purchasing an additional 45,586 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.
In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 30,000 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $36.19, for a total value of $1,085,700.00. Following the sale, the chairman now owns 3,180,709 shares of the company’s stock, valued at approximately $115,109,858.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 5,700 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total value of $202,692.00. Following the completion of the sale, the chief executive officer now directly owns 3,259,263 shares in the company, valued at approximately $115,899,392.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 137,736 shares of company stock worth $4,866,186. Corporate insiders own 23.70% of the company’s stock.
Several equities analysts have issued reports on the company. ValuEngine raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday. BidaskClub raised LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Wednesday, February 28th. Finally, Canaccord Genuity reissued a “hold” rating and set a $33.00 price target on shares of LeMaitre Vascular in a report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $34.00.
NASDAQ LMAT opened at $37.73 on Friday. LeMaitre Vascular Inc has a 52-week low of $24.25 and a 52-week high of $39.88. The stock has a market cap of $731.15, a P/E ratio of 43.87, a P/E/G ratio of 2.59 and a beta of 0.54.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.01. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. The firm had revenue of $26.15 million for the quarter, compared to analyst estimates of $26.23 million. During the same quarter last year, the company posted $0.13 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. analysts expect that LeMaitre Vascular Inc will post 0.98 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, April 5th. Investors of record on Thursday, March 22nd were issued a dividend of $0.07 per share. The ex-dividend date of this dividend was Wednesday, March 21st. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.74%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.06. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 32.56%.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/advisor-group-inc-has-223000-holdings-in-lemaitre-vascular-inc-lmat.html.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.